A phase III, randomized, double-blind, placebo-controlled, multinational trial of Iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT Trial)

Francis J. Giles, Carole B. Miller, David D. Hurd, John R. Wingard, Thomas R. Fleming, Stephen T. Sonis, Williamson Z. Bradford, Janis G. Pulliam, Elias J. Anaissie, Roy A. Beveridge, Mark M. Brunvand, Paul J. Martin, Hartmut Bertz, Richard Clark, Daniel R. Couriel, Stephen D. Gore, Marcos De Lima, Godfrey Morgenstern, Anne Parker, Eckard ThielKenneth W. Zamkoff

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Fingerprint

Dive into the research topics of 'A phase III, randomized, double-blind, placebo-controlled, multinational trial of Iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT Trial)'. Together they form a unique fingerprint.

Medicine & Life Sciences